AxoGen, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael D. Dale
- Full Time Employees
- 451
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 13631 Progress Boulevard Alachua FL United States of America 32615
- IPO Date
- Dec 17, 1986
- CIK
- 0000805928
- Website
- axogeninc.com
- Similar Companies
- Business
- AxoGen, Inc. (NASDAQ: AXGN) develops and commercializes surgical solutions for peripheral nerve regeneration and repair; its comprehensive product portfolio includes Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa extracellular matrix product used to wrap and protect damaged peripheral nerves; AxoGuard HA+ Nerve Protector, a porcine submucosa extracellular matrix base layer coated with a proprietary hyaluronate-alginate gel to enhance nerve gliding and provide short- and long-term protection; AxoGuard Nerve Cap, a porcine submucosa extracellular matrix product that protects peripheral nerve ends to reduce symptomatic neuroma formation; and Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft used to protect and separate tissues during surgical repair. Founded in 2002 and headquartered in Alachua, Florida, the company serves reconstructive plastic surgeons, hand surgeons, orthopedic surgeons, oral and maxillofacial surgeons, and other healthcare providers treating traumatic injuries, breast reconstruction, nerve decompression, oral/maxillofacial procedures, and pain management; its products address over 900,000 annual procedures in a market exceeding $2.7 billion and are available in the United States, Canada, the United Kingdom, South Korea, and select European and international markets. In December 2025, AxoGen received FDA approval of its Biologics License Application for Avance Nerve Graft (arwx), transitioning the product from human cells, tissues, and cellular/tissue-based classification to a regulated biologic with 12 years of market exclusivity; the approval follows the RECON pivotal study completion and supports expanded commercialization. Recent financial performance reflects strong growth, with Q3 2025 revenue of $60.1 million, up 23.5% year-over-year, double-digit increases across all markets, raised full-year 2025 guidance to at least $222.8 million (19% growth), gross margins of 73-75%, and expectations for net cash flow positivity; payer coverage expansions added 18.1 million lives in 2025, reaching over 64% commercial coverage.
AxoGen, Stock Of The Day, Offers Entry After Bullish Rebound
AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam
Axogen, Inc. (AXGN) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
Axogen, Inc. (AXGN) Q1 2026 Earnings Call Transcript
AxoGen (AXGN) Q1 Earnings Lag Estimates
Axogen, Inc. Reports First Quarter 2026 Financial Results
Capricorn Fund Makes a Huge Bet on Nerve Repair With 687,000 Share Axogen (AXGN) Investment Worth $22.4 Million
AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth
AxoGen (AXGN) Surges 7.5%: Is This an Indication of Further Gains?
Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026
SG Americas Securities LLC Increases Stock Holdings in AxoGen, Inc. $AXGN
AxoGen, Inc. $AXGN Shares Sold by JPMorgan Chase & Co.
Exchange Traded Concepts LLC Sells 26,743 Shares of AxoGen, Inc. $AXGN
Axogen Insider Sale of 5,221 Shares Follows 20% Revenue Growth in 2025. Here's What to Know
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth
ArrowMark Colorado Holdings LLC Buys 332,498 Shares of AxoGen, Inc. $AXGN
AxoGen Says BLA Approval Secures Avance Use, Boosts Coverage Talks and Reimbursement Momentum
AxoGen Touts FDA BLA Win, Targets 18% Growth and Wider Nerve Repair Adoption at Raymond James Conference
Axogen, Inc. (AXGN) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript